Table 3.

Surgical and pathological features of patients receiving conversion surgery (n = 30).

Characteristics	Total (n = 30)
Days from systemic therapy to surgery, days (median, range)	90.5 (53–456)
Anti-PD-1 antibody used
Sintilimab	14 (46.7%)
Toripalimab	8 (26.7%)
Tislelizumab	4 (13.3%)
Camrelizumab	3 (10%)
Pembrolizumab	1 (3.3%)
Infusions of anti-PD-1 antibody, times (median, range)	4 (3-21)
Major tumor size, cm (median, range)	9.3 (3.5-15)
Tumor number
Solitary	25 (83.3%)
Multiple	5 (16.7%)
Open surgery, n (%)	30 (100%)
Time of surgery, mins (median, range)	180 (150–220)
Blood loss, mL (median, range)	400 (100-1500)
Blood transfusion	3 (10.0%)
Postoperative hospital stay, days (median, range)	14 (8-31)
Micro-vascular invasion, n (%)	8 (26.7%)
Pathological complete response, n (%)	10 (33.3%)